Lantheus Holdings, Inc. $LNTH Holdings Boosted by California Public Employees Retirement System

California Public Employees Retirement System raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,776 shares of the medical equipment provider’s stock after acquiring an additional 12,060 shares during the period. California Public Employees Retirement System’s holdings in Lantheus were worth $9,995,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Abel Hall LLC raised its stake in shares of Lantheus by 4.6% in the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after buying an additional 172 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Blue Trust Inc. increased its stake in Lantheus by 30.3% in the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after acquiring an additional 230 shares during the period. Vident Advisory LLC raised its position in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after purchasing an additional 230 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 275 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LNTH. B. Riley Financial lifted their price objective on Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Truist Financial raised their target price on Lantheus from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $115.00 price target on shares of Lantheus in a research note on Monday, June 29th. Mizuho upped their price target on Lantheus from $115.00 to $120.00 and gave the company a “market outperform” rating in a research report on Wednesday, July 15th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a report on Thursday, May 7th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.43.

Lantheus Stock Performance

NASDAQ:LNTH opened at $104.82 on Friday. The stock has a market capitalization of $6.82 billion, a P/E ratio of 25.26 and a beta of -0.06. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.86. The firm has a 50 day moving average of $103.36 and a 200-day moving average of $85.56.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same period in the prior year, the company earned $1.53 EPS. Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.